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v-Conotoxins selective for N-type calcium channels
are useful in the management of severe pain. In an at-
tempt to expand the therapeutic potential of this class,
four new v-conotoxins (CVIA–D) have been discovered
in the venom of the piscivorous cone snail, Conus catus,
using assay-guided fractionation and gene cloning.
Compared with other v-conotoxins, CVID has a novel
loop 4 sequence and the highest selectivity for N-type
over P/Q-type calcium channels in radioligand binding
assays. CVIA2D also inhibited contractions of electri-
cally stimulated rat vas deferens. In electrophysiologi-
cal studies, v-conotoxins CVID and MVIIA had similar
potencies to inhibit current through central (a1B-d) and
peripheral (a1B-b) splice variants of the rat N-type cal-
cium channels when coexpressed with rat b3 in Xenopus
oocytes. However, the potency of CVID and MVIIA in-
creased when a1B-d and a1B-b were expressed in the ab-
sence of rat b3, an effect most pronounced for CVID at
a1B-d (up to 540-fold) and least pronounced for MVIIA at
a1B-d (3-fold). The novel selectivity of CVID may have
therapeutic implications. 1H NMR studies reveal that
CVID possesses a combination of unique structural fea-
tures, including two hydrogen bonds that stabilize loop
2 and place loop 2 proximal to loop 4, creating a globular
surface that is rigid and well defined.
Predatory marine gastropods of the genus Conus (cone
snails) represent a diverse family of marine molluscs that use
venom for prey capture. The venom of each species contains a
unique array of more than 100 peptides, whose pharmaceutical
potential remain largely unexploited (1). Different classes of
conotoxins have evolved to target ion channels and receptors
for the successful capture of fish, molluscs, or worms (2, 3). One
important class, the v-conotoxins (Table I) isolated from pis-
civorous species, inhibits neuronal voltage-sensitive calcium
channels (VSCCs)1 found in mammals (4). v-Conotoxins have
selectivity for N-type (e.g. MVIIA and GVIA) or P/Q-type (e.g.
MVIIC) VSCCs, making them widely used research tools for
defining the distribution and role of neuronal VSCCs (4–8). In
addition to their use as research tools, animal studies have
shown that v-conotoxins that target N-type VSCCs have clin-
ical potential in ischemic brain injury (9) and pain (10). How-
ever, v-conotoxins presently available are not ideal therapeu-
tics, despite their selectivity and potency and the dominant role
of N-type VSCCs at synapses in carrying nociceptive informa-
tion in the spinal cord (11). For example, intrathecal MVIIA
causes a variety of neurological side effects of unknown origin
(12). Another N-type VSSC selective v-conotoxin, GVIA, disso-
ciates slowly from N-type VSCCs (13, 14) and, accordingly, may
be difficult to administer in a clinical setting. Other v-conotox-
ins are less selective for N-type VSCCs and are not considered
useful therapeutic candidates.
A number of central and peripheral splice variants of the
N-type VSCC have been reported (14). However, calcium chan-
nel probes with greater selectivity are required to help under-
stand the role(s) played by the various forms of the N-type
VSCC in normal and disease states. Here we report the isola-
tion and characterization of four new v-conotoxins (CVIA—D,
see Table I) discovered in the venom of the piscivorous cone
snail, Conus catus. One of these, CVID, has a number of novel
structural features that underlie an enhanced ability to dis-
criminate between N-type (a1B) and P/Q-type (a1A) VSCCs, as
well as between splice variants of the a1B expressed in oocytes
in the presence or absence of rat b3.
EXPERIMENTAL PROCEDURES
Crude Venom Extraction—37 specimens of C. catus (average length 4
cm) were collected from the southern Great Barrier Reef. Crude venom
duct contents were extracted with 30% acetonitrile/water acidified with
0.1% trifluoroacetic acid and centrifuged. Soluble material was lyophi-
lized and stored at 220 °C prior to use.
Isolation of Native Peptides—The crude venom extract (12 mg) was
fractionated using semi-preparative RP-HPLC (10 mm C18, 1.0 3 25
cm, Vydac) eluted at 2.5 ml/min with a linear gradient of 0–60% solvent
B over 60 min, then to 80% solvent B over 20 min, using a Waters 600
solvent delivery system (solvent A, 10% acetonitrile, 0.1% trifluoroace-
tic acid; solvent B, 90% acetonitrile, 0.09% trifluoroacetic acid). Inhibi-
tion of 125I-GVIA binding to rat brain membrane (see below) identified
six 1-min fractions eluting at 17, 18, 22, 23, 26, and 27 min that
contained v-conotoxins. The v-conotoxins in each fraction were further
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purified by size exclusion HPLC (Superdex HR10/30, Amersham Phar-
macia Biotech) eluted with 30% acetonitrile, 0.1% trifluoroacetic acid at
0.5 ml/min. Active fractions were finally rechromatographed by analyt-
ical RP-HPLC (5 mm C18, 0.46 3 25 cm, Vydac) eluted at 1 ml/min with
a linear gradient of 0–50% solvent B over 45 or 90 min. Peaks detected
at 214 nm were collected and sequenced. Screening of the venom of
other Australian cone snails, including the piscivorous Conus striatus,
Conus tulipa, Conus geographus, and Conus magus, only identified
sequences corresponding to known v-conotoxins.
Sequencing of Native Peptides—The purified peptides (;100 pmol)
were reduced in the presence of TCEP, 50 mM ammonium acetate at pH
4.5 (37 °C for 1 h), and then alkylated in the presence of maleimide
(37 °C, 1 h). The alkylated peptides were purified by RP-HPLC, applied
to a Biobrene-treated glass fiber filter, and analyzed by Edman chem-
istry using an Applied Biosystems, Inc., model 470A protein sequencer.
Alkylation of peptides with maleimide allowed their cysteine residues
to be observed as phenylthiohydantoin-Cys-maleimide doublets (diaste-
reomers), and Ser was confirmed by the presence of dehydroserine. The
high number of serine, threonine, and cysteine residues present in each
conotoxin resulted in a relatively rapid decrease in the amino acid
yields in successive cycles; however, complete sequences were obtained
in each case. The low serine signals were accompanied by the presence
of large dehydroserine peak.
Gene Isolation and Characterization—Ducts from two specimens of
C. catus were emulsified, and poly(A)1-tailed mRNA was extracted
using the QuickPrep mRNA purification system (Amersham Pharmacia
Biotech). Strand-1 cDNA was 39 end-synthesized from the C. catus
poly(A)1 mRNA templates using a NotI-d(T)18 bifunctional primer (59-
AACTGGAAGAATTCGCGGCCGCAGGAAT18) (Amersham Pharmacia
Biotech) extended with Superscript II reverse transcriptase (Life Tech-
nologies, Inc.). The resultant cDNA templates were used to manufac-
ture double-stranded cDNA using a RNase H/DNA polymerase proce-
dure (cDNA Timesaver system, Amersham Pharmacia Biotech).
Marathon adaptors (CLONTECH) were added to the 59 and 39 ends of
the ds-cDNA molecules to complete the cDNA construction. An oligo-
nucleotide PCR primer (R-301A 59-atcatcaaaATGAAACTGACGTG)
was designed from a consensus of aligned coding sequences from cono-
toxins with a 6-cysteine/4-loop framework comprising published (15, 16)
and unpublished data.2 The primer included a translation start site
(underlined) and 9 base pairs of 59-untranslated sequence (lowercase).
This forward PCR primer was designed to work in conjunction with the
reverse ANCHOR primer (59- AACTGGAAGAATTCGCGGCCGCAG-
GAAT) that was homologous to the adaptor at the 39 termini of the
ds-cDNA templates.
PCR was carried out on samples containing ds-cDNA from C. catus,
the R-301A primer, the ANCHOR primer, AmpliTaq Gold polymerase
(PerkinElmer Life Sciences), the manufacturer’s AmpliTaq buffer, 25
mM MgCl2, and 100 mM deoxynucleotides. The samples were incubated
in a PTC-100 thermal cycler (MJ Research, Bresatec, Australia) at
95 °C for 2 min (1 cycle), 95 °C for 30 s, 55 °C for 60 s, 72 °C for 90 s (35
cycles), and 72 °C for 10 min (1 cycle). The PCR products were assessed
on agarose gels and, when necessary, isolated and purified using
BRESAspin gel extraction systems (Bresatec, Australia). The purified
PCR products were blunt end-cloned into dephosphorylated Sma-1
cut pUC-18 plasmid vector DNA (Amersham Pharmacia Biotech) and
sequenced using the pUC-18 forward and reverse primers (Amer-
sham Pharmacia Biotech), dideoxy terminator sequencing chemis-
tries (PerkinElmer Life Sciences) on Applied Biosystems, Inc., 377
sequencers.
Peptide Synthesis—CVIA–D were each manually synthesized,
deprotected, and cleaved from resin as described previously (17, 18).
O-(7-Azabenzotriazol-1-yl)-N,N,N9,N9-tetramethyluronium hexafluoro-
phosphate was used in place of O-(benzotriazol-1-yl)-N,N,N9,N9-tetra-
methyluronium hexafluorophosphate for difficult sections. The pure,
reduced peptides (0.02–0.05 mM) were oxidized in aqueous 0.33 M
NH4Oac, 0.5 M guanidinezHCl (pH 7.5–8.0, adjusted with 0.1 M
NH4OH). The peptide solutions were then stirred for 2–4 days at 4 °C
in the presence of reduced and oxidized glutathione (molar ratio 1:100:
10) to achieve oxidation. Oxidized peptides were purified by preparative
RP-HPLC (18).
Peptide Quantitation—Peptides were quantified initially by tripli-
cate amino acid analysis (19) and then by RP-HPLC (HP 1100) using an
external reference standard for each peptide. Stability studies in phys-
iological saline solutions showed that nonspecific binding of these pep-
tides to glass or polypropylene was minimal.
Mass Spectrometry—Mass spectra were acquired on a PE-Sciex API
III triple quadrupole electrospray mass spectrometer (MS) in positive
ion mode (m/z 500–2000, at 0.1–0.2-Da steps, declustering potentials
of 10–90 V, and dwell times of 0.4–1.0 s). Data were deconvoluted
(MacSpec 3.2, Sciex, Canada) to obtain the molecular weight from the
multiply charged species. MS was used to confirm purity and to monitor
peptide oxidation. Native and synthetic CVIA2D were compared on a
5-mm C18 column (0.21 3 25 cm, Vydac) eluted with 0.05% trifluoro-
acetic acid for 2 min and then with a linear gradient to 80% solvent B
(solvent B, 90% acetonitrile, 0.045% trifluoroacetic acid) over 80 min at
a flow rate of 130 ml/min, using a Hewlett-Packard 1100 pump and MS
detection.
Radioligand Binding—Radioligand binding were performed on rat
brain membrane incubated in the following (mM): 20 HEPES (pH 7.2),
75 NaCl, 0.1 EDTA, 0.1 EGTA, 2 leupeptin, 0.5 units of aprotinin, and
0.1% bovine serum albumin, as described previously (18, 20, 21). 125I-
[Tyr22]GVIA, 125I-CVID, 125I-MVIIA, and 125I-MVIIC were prepared
using IODOGEN, stored at 4 °C, and used within 3 weeks. 125I-CVID
and 125I-MVIIA both eluted ;3 min after CVID or MVIA, respectively,
as single homogenous peaks on RP-HPLC. Cold iodinated CVID (127I-
CVID) was also prepared and quantified by HPLC. 127I-CVID coeluted
with 125I-CVID, and MS confirmed it as the monoiodinated species. For
displacement studies, [125I-Tyr22]GVIA, 125I-MVIIA, or 125I-MVIIC (7
pM diluted with assay buffer) were incubated with increasing concen-
trations of cold peptide. Saturation binding studies were performed
with freshly prepared 125I-CVID and 125I-MVIIA (n 5 4 experiments).
On-rate and off-rate experiments were performed at 23 °C in single
50-ml polypropylene tubes containing 125I-CVID or 125I-MVIIA (30 pM
diluted with assay buffer). On-rate experiments commenced with the
addition of rat brain membrane, and off-rate experiments commenced
with the addition of excess CVID or MVIIA (1027 M) following a 30-min
incubation of rat brain membrane with 125I-CVID or 125I-MVIIA (30
pM), respectively. At defined intervals, aliquots (300 ml) were filtered
(25-mm Whatman GF/B treated with 0.6% polyethyleneimine), and the
filtrates were rapidly washed three times with ice-cold wash buffer.
Nonlinear regressions were fitted to each experiment (n 5 3 data points
per experiment) with Prism software (GraphPad, San Diego, CA).
Rat Vas Deferens—Male Wistar rats (250–350 3 g) were killed by
2 R. J. Lewis, K. J. Nielsen, D. J. Craik, M. L. Loughnan, D. A. Adams,
I. A. Sharpe, T. Luchian, D. J. Adams, T. Bond, L. Thomas, A. Jones,
J.-L. Matheson, R. Drinkwater, P. R. Andrews, and P. F. Alewood,
unpublished data.
TABLE I
Sequence and VSCC selectivity of selected v-conotoxins
Namea Sequenceb Selectivityc Ref.
Loop 1 2 3 4
CVIA CKSTGASCRRTSYDCCTGSCRS--GRC* N Present study
CVIB CKGKGASCRKTMYDCCRGSCRS--GRC* N/P/Q Present study
CVIC CKGKGQSCSKLMYDCCTGSCSRR-GKC* N/P/Q Present study
CVID CKSKGAKCSKLMYDCCSGSCSGTVGRC* N Present study
GVIA CKSOGSSCSOTSYNCCR-SCNOYTKRCY* N 57
TVIA CLSOGSSCSOTSYNCCR-SCNOYSRKCY* N 4
MVIIA CKGKGAKCSRLMYDCCTGSCRS--GKC* N 58
MVIIC CKGKGAPCRKTMYDCCSGSCGRR-GKC* P/Q 59
SVIB CKLKGQSCRKTSYDCCSGSCGRS-GKC* N/P/Q 51
a v-Conotoxins from the venom of piscivorous C. catus (C), C. geographus (G), C. tulipa (T), C. magus (M), and C. striatus (S) are shown.
b All v-conotoxins are C-terminally amidated (*).
c Selectivity determined from relative potencies to displace 125I-GVIA (N-type) and 125I-MVIIC (P/Q-type) binding to rat brain membrane.
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cervical dislocation and exsanguinated. Prostatic halves of each vas
deferens were mounted under 0.5 3 g tension in 5-ml organ baths
containing physiological solution containing the following (mM): 119
NaCl, 4.7 KCl, 1.17, MgSO4, 1.18 KH2PO4, 25.0 NaHCO3, 5.5 glucose,
2.5 CaCl2, 0.026 EDTA, at 37 °C and bubbled with 5% CO2 in O2 (pH
7.4). After 45 min of equilibration, electrical field stimulation every 3
min (single 55 V, 0.1-ms duration pulses generated by a Grass S44
stimulator) were applied via two platinum-stimulating electrodes
straddling the tissue. Isometric contractions were measured using a
force transducer (F-60, Narco Bio-System) and recorded digitally on a
Power Macintosh computer using Chart version 3.5.6/s software and
a MacLab/8 s data acquisition system (ADInstruments, Australia) at a
sampling frequency of 200 Hz. Evoked contractions were abolished by
tetradotoxin (0.1 mM), indicating that they were of neurogenic origin.
Conotoxins were added cumulatively at 18-min intervals, with allow-
ance made for a small (0.16% /min) deterioration of the evoked re-
sponse. CVID effect on ATP (3 3 1023 M, Sigma) and norepinephrine
(1024 M, Sigma) responses in the bisected epididymal portion of the rat
vas deferens was also determined. Dose-response data (means 6 S.E.;
n 5 5) were analyzed using Prism software.
Oocyte Injection and Recording—Oocytes were surgically removed
from mature Xenopus laevis frogs anesthetized by submersion in 0.1%
ethyl m-aminobenzoate (MS 222). Stage V–VI oocytes were prepared for
injection by dissociation in Ca21-free solution containing the following
(mM): 96 NaCl, 2 KCl, 1 MgCl2, 5 HEPES (pH 7.4), plus 1 mg/ml
collagenase (Sigma, type I) for 1 h at room temperature. Oocytes,
maintained in storage solution containing (mM) 96 NaCl, 2 KCl, 1
CaCl2, 1 MgCl2, 5 HEPES, 5 pyruvate, plus 50 mg/ml gentamicin (pH
7.4), were injected with 25–50 ng of total cRNA using a precision
injector (Drummond “Nanojet”) and incubated at 18 °C for 325 days.
Injected cRNA obtained using an Ambion mMessage mMachine kit
comprised rat brain peripheral (a1B-b) or central (a1B-d) subunits of the
N-type VSCC expressed in the absence or presence (1:1 ratio) of the rat
b3 subunit provided by D. Lipscombe (12). Recordings were made in a
nominally Ca21-free solution containing (mM) 85 tetraethylammonium,
5 BaCl2, 5 KCl, 5 HEPES, adjusted to pH 7.4 with methanesulfonic acid
perfused at a rate of ;10 ml/min. Depolarization-activated Ba21 cur-
rents were recorded using a GeneClamp 500B two-electrode voltage
clamp amplifier (Axon Instruments Inc., Foster City, CA) at room
temperature (21223 °C). Voltage and current electrodes were filled
with 3 M KCl and had final resistances of 0.2–1.0 MV. VSCC currents in
oocytes were evoked by a step depolarization to 0 mV from a holding
potential of 280 mV using pClamp programs (Axon Instruments Inc).
The linear membrane capacitative and leak currents were subtracted
using a 2P/4 pulse protocol. Membrane currents were sampled at 10
kHz and filtered at 2 kHz. Oocytes showing ,15% change in peak
current amplitude over a 10-min incubation period were used in these
studies to avoid effects associated with current run down. Oocytes that
exhibited a slowly developing Cl2 current were discarded, and in con-
trol experiments on the remaining oocytes, BAPTA injection did not
affect the Ba21 current, indicating that this current was not contami-
nated by Ca21-activated Cl2 current. Perfusion was stopped, and cu-
mulative additions of v-conotoxins were added to a Teflon chamber (0.8
ml volume) to achieve rapid mixing. Inhibition of peak Ba21 current
amplitude was measured when the inhibitory effects of each concentra-
tion of MVIIA and CVID approached steady state values, typically
requiring a 5–7-min incubation to achieve ,2% change in peak current
amplitude per min. Data (means 6 S.E.; n 5 3–5) were fitted with
nonlinear regressions using Origin software.
1H NMR and Three-dimensional Structure Calculations—All NMR
experiments were recorded on a Bruker ARX 500 spectrometer
equipped with a z-gradient unit, or a Bruker DMX 750 spectrometer
equipped with an x,y,z-gradient unit. The Ha chemical shifts were
obtained from spectra of CVIA–D in 95% H2O, 5% D2O (pH 2.5–3.5) at
293 K, and restraints for three-dimensional structure calculations of
CVID were obtained from spectra recorded at 280 and 293 K at pH 3
and 5.5 (18). Structures were calculated using the torsion angle dynam-
ics/simulated annealing protocol in XPLOR version 3.8 (22–25), as
described previously (20).
RESULTS
Isolation and Synthesis of v-Conotoxins from C. catus—The
four v-conotoxins, CVIA2D, were isolated from the crude
venom of C. catus using activity-directed fractionation. Each
comprised ,1% of total venom peptide as determined by HPLC
(214 nm) or MS detection (m/z 500–2000). The amino acid
sequences of CVIA and CVIB were cosequenced at a 3:2 ratio,
whereas CVIC and CVID were obtained from separate frac-
tions. Synthetic C-terminally amidated CVIA, CVIC, and CVID
gave retention times and masses that were indistinguishable
from the corresponding native peptides (Fig. 1), thus CVIA,
CVIC, and CVID were determined to be C-terminally ami-
dated. For each peptide, the oxidized form eluted earlier than
the reduced form.
Gene Isolation and Characterization—PCR of the C. catus
venom duct cDNA templates produced a DNA product of ap-
proximately 3802500 base pairs (data not shown). A relatively
broad DNA band indicated the presence of a composite PCR
product. Subsequent sequence analysis of more than 100 clones
derived from the PCR product libraries confirmed this obser-
vation. The PCR products contained peptides of the v- and
d-conotoxin types, as well as sequences from at least two other
conotoxin families yet to be assigned. Within the v-conotoxin
sequences isolated were two that translated to putative mature
peptides identical to the CVIA and CVID sequences. Despite an
extensive screening of the two C. catus PCR product libraries,
clones for the conotoxins CVIB and CVIC were not located, and
the CVID clone was located in only one specimen. The complete
nucleotide and predicted amino acid sequences derived for
CVIA and CVID are shown in Fig. 2 and are aligned with the
sequences for MVIIA and GVIA. Homology screening of public
nucleotide and amino acid data bases with the CVIA and CVID
sequences indicated that both sequences were unique.
Radioligand Binding—Synthetic CVIA2D, GVIA, MVIIA,
and MVIIC each fully displaced 125I-GVIA (defining N-type
VSCCs) and 125I-MVIIC (defining P/Q-type VSCCs) binding to
crude rat brain membrane (Fig. 3; Table II). GVIA, MVIIA, and
FIG. 1. HPLC/MS of native and synthetic v-conotoxins from C.
catus. A, extracted ion chromatogram of 10 ml of C. catus crude venom
(m/z 800–1400) revealing CVIA, CVIC, and CVID (CVIB was not
detected in this batch of crude venom). B, extracted ion chromatogram
for a mix of synthetic CVIA, CVIB, CVIC, and CVID (m/z 800–1400).
Insets show the reconstructed spectra for CVIA, CVIB, CVIC, and
CVID. Retention times and masses for native and synthetic CVIA,
CVIC, and CVID were comparable.
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CVID had similarly high affinity for the N-type VSCC (pIC50 6
S.E. values of 10.4 6 0.05, 10.3 6 0.03, and 10.2 6 0.03 M,
respectively). In comparison, CVIA was a moderate inhibitor,
and CVIB and CVIC were relatively poor inhibitors at the
N-type VSCC. GVIA, MVIIA, and CVID also fully displaced
125I-MVIIA, with potencies (IC50 values of 49, 29, and 50 pM,
respectively) similar to those obtained for displacement of 125I-
GVIA. At the P/Q-type VSCC MVIIC had highest affinity
(pIC50 9.2 6 0.04 M); CVIB and CVIC were moderate inhibi-
tors; MVIIA, CVIA, and MVIIA were poor inhibitors; and
CVID was an exceptionally weak inhibitor (IC50 55 mM) (Fig. 3B
and Table II).
Saturation binding studies indicated that 125I-CVID and
125I-MVIIA (67 6 11 and 37 6 12 pM, respectively) had poten-
FIG. 2. Nucleotide and predicted amino acid sequence for the CVIA and CVID peptides. A, ClustalW alignment of nucleotide sequences
for the conopeptides CVIA, CVID, GVIA (16), and MVIIA (Australian C. magus),2 with start and stop coding sequences underlined. The first 14
residues of CVIA and CVID were generated as part of the PCR primer R-301A. However, subsequent 59-rapid amplification of cDNA ends PCR
indicated that this sequence was identical to the native coding sequence for both peptides (data not shown). The position of the cleavage site
between the pre-pro and mature peptide sequences is indicated by an arrow. B, ClustalW alignment of the amino acid sequences for the
conopeptides CVIA, CVID, MVIIA, and GVIA. The predicted amino acid sequence for MVIIA from A was the same as previously reported (55). The
predicted signal (positions 1–21) and propeptide (positions 22–45) regions of the leader sequences are highlighted by dashed lines (56). An arrow
indicates the position of the known cleavage site separating the pre-pro and mature peptides of the four sequences. The intercysteine (C) loop
sequences for the mature peptides are also indicated. Conserved residues are dark shaded, and conservative changes in amino acids are light
shaded.
Novel v-Conotoxins Inhibit Neuronal Ca21 Channels35338
 by on Septem
ber 7, 2006 
w
w
w
.jbc.org
D
ow
nloaded from
 
cies slightly lower than CVID and MVIIA in rat brain mem-
brane, and both appeared to occupy a single class of receptor
(Fig. 4). In paired experiments (n 5 4), 125I-CVID (0.07 6 0.03
pmol/mg protein) bound to 31% fewer receptors in rat brain
membrane than 125I-MVIIA (0.10 6 0.04 pmol/mg protein) (p 5
0.049, paired two-tailed t test), and 125I-CVID had half the
nonspecific binding of 125I-MVIIA (Fig. 4). Despite this differ-
ence in the density of receptor sites recognized, displacement
assays did not reveal a component of 125I-GVIA or 125I-MVIIA
binding that was not displaced by CVID. 127I-CVID (IC50 0.44
nM) also fully displaced 125I-MVIIA binding to rat brain with a
Hill slope of unity. However, saturation binding studies have
limited power to resolve binding sites of similar affinity, and a
lower affinity binding site comprising 30% of receptors would
be under-represented with the concentration of 125I-MVIIA
used in the displacement assays (20% of its Kd concentration).
Displacement of higher concentrations of 125I-MVIIA by
MVIIA, GVIA, CVID, or 127I-CVID also did not identify a sig-
nificant resistant component, possibly due to the reduction in
the signal to noise of the assay with increased labeled ligand
concentrations (data not shown). The difference in Bmax did not
arise from differences in binding kinetics; 125I-CVID and 125I-
MVIIA had similar kon values (0.024 and 0.08 min
21 pM21,
after adjusting for koff) and koff values (0.56 and 0.53 min
21,
respectively). The Kd values for
125I-CVID and 125I-MVIIA cal-
culated from kinetic data (23 and 7 pM, respectively) were
similar to the estimates obtained from saturation binding stud-
ies (67 and 37 pM, respectively).
Rat Vas Deferens—CVIA–D inhibited electrically stimulated
rat vas deferens contractions (Fig. 5A). The rank order of po-
tency was GVIA . CVID ’ MVIIA . CVIA . CVIC . CVIB
(Fig. 5B and Table II). Inhibition of the nerve-evoked responses
in rat vas deferens was positively correlated with displacement
of 125I-GVIA binding across the v-conotoxins tested (log(rat vas
deferens IC50) 5 0.78(log(
125I-GVIA IC50) 1 0.1) (r
2 5 0.92)).
CVID and MVIIA gave Hill slopes significantly greater than
unity (2.9 and 3.3, respectively), whereas CVIA-C and GVIA
gave Hill slopes that were not significantly different from
unity. The origin of these differences is unclear; however, dif-
ferences in N-type versus P/Q-type VSCC selectivity do not
appear to be a contributing factor. The nonlinear relationship
between calcium influx and transmitter release (26) is expected
to give rise to a Hill slope greater than unity. Base-line tension
was not affected by this series of peptides, and CVID (3 3 1027
M) had no significant effect on the size of ATP and norepineph-
rine-induced contractions in rat vas deferens (data not shown,
n 5 3). A residual component of rat vas deferens contractile
activity remained at saturating concentrations of CVID,
MVIIA, and GVIA (14.8% (95% CI, 12–18%), 10.5% (7–14%),
and 10% (6–14%), respectively) (Fig. 5B).
Xenopus Oocytes—Two-electrode voltage clamp studies re-
vealed that CVID and MVIIA were potent inhibitors of ionic
currents through peripheral (a1B-b) and central (a1B-d) splice
variants of the rat N-type calcium channels expressed in Xeno-
pus oocytes in the presence or absence of rat b3 (Fig. 6; Table
III). The voltage dependences of activation of these VSCC con-
ductances were unaffected by CVID or MVIIA (data not
shown). CVID and MVIIA had similar potencies to inhibit
depolarization-activated inward Ba21 current arising from
a1B-b or a1B-d coexpressed with rat b3 (Fig. 6, C and D). At the
a1B-b, the potency of both MVIIA and CVID increased 10-fold in
the absence of rat b3. At the a1B-d, in contrast, CVID potency
increased up to 540-fold, whereas MVIIA potency was only
slightly increased in the absence of excess rat b3. Inhibition of
the inward Ba21 current by CVID was slowly reversed upon
washout, and neither conopeptide inhibited the small endoge-
nous calcium channel current (,5 nA) seen in oocytes that were
not injected with cRNA (data not shown). For the a1B/b subunit
combinations tested, a relatively small residual N-type current
(;10% of maximum peak current) remained in the presence of
saturating concentrations of CVID or MVIIA (Fig. 6, C and D).
The residual component had reversal potentials and inward
current maxima typical of N-type VSCCs and were completely
blocked by bath application of 100 mM Cd21 (data not shown),
suggesting that both peptides are unable to occlude completely
current through open N-type VSCCs. Further studies are re-
quired to confirm that CVID and MVIIA are allosteric inhibi-
tors of the N-type VSCC, as suggested for GVIA from single
channel data (27). VSCC chimera studies indicate that GVIA
may occlude the pore of the N-type VSCC (28).
1H NMR Studies—The two-dimensional 1H NMR spectra of
v-conotoxins CVIA2D were each assigned using standard pro-
tocols (29). As with other v-conotoxins we have examined (18,
20, 30), peaks were well dispersed, and there was little overlap.
CVIA–D secondary shifts closely paralleled those of MVIIA
(Fig. 7), whose structure is well defined (30), indicating that the
overall fold and disulfide connectivity of these peptides are the
FIG. 3. v-Conotoxin potency at N-type and P/Q-type VSCCs in
rat brain. A, potency at N-type VSCCs measured by displacement of
125I-GVIA binding. B, potency at P/Q-type VSCCs measured by dis-
placement of 125I-MVIIC binding. Displacement data was best fit to a
single-site competition model (shown). C, selectivity for N-type versus
P/Q-type VSCCs in rat brain. Shown are the means 6 S.E. for pIC50
(N-type) and pIC50 (P/Q-type).
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same. Secondary Ha shift analysis has been shown to be a
sensitive discriminator of disulfide-bonded isomers of other
conotoxins (31) and can also be used to identify the location, but
not the nature, of local conformational differences across a set
of structurally related peptides (32). The secondary Ha shifts of
CVIA and CVIB, which have the same loop sizes as MVIIA, are
almost identical to those of MVIIA. The secondary Ha shifts of
CVIC are also similar to those of MVIIA, apart from loop 4
where the loop sizes are different. In this case, the structure of
CVIC would be better approximated by MVIIC, which has the
same sized loop 4.
The greatest difference in Ha secondary shifts compared
with MVIIA was seen in loops 2 and 4 of CVID. Although
differences in loop 4 are not surprising given that CVID has
two additional residues, the differences in loop 2 are remark-
able given the similarities between MVIIA and CVID at loop 2.
The secondary shifts of residues 9–14 in loop 2 of CVID follow
the same pattern of those in MVIIA but are of greater magni-
tude, indicating that the structure of loop 2 in CVID may be
more stabilized. This could stem from a long range interaction
with loop 4, where the major differences in primary structure
are located. Loop 2 has previously been the least defined region
of v-conotoxin structures, with residues of this loop character-
ized by relatively broad peaks in the 1H NMR spectra, indica-
tive of conformational exchange (30, 33). This lack of structure
definition has hindered attempts to understand the crucial role
loop 2 plays in activity, function, and selectivity of v-conotox-
ins, particularly that of the principal binding determinant
Tyr13, as well as residues of secondary importance such as
Leu11 and Arg10 in MVIIA (34). Because no line broadening is
observed in loop 2 or elsewhere in CVID but is prominent in
loop 2 of MVIIA, CVID may provide a significantly improved
structural template for pharmacophore development. Given
that the significant differences in secondary Ha shifts for res-
idues in loops 2 and 4 in CVID preclude accurate modeling of
CVID from existing v-conotoxins structures, and given its en-
hanced N-type selectivity and structural stability, we deter-
mined the three-dimensional structure of CVID using 1H NMR
spectroscopy, as described below.
Three-dimensional Structure of v-Conotoxin CVID—CVID
structures were calculated based on a total of 481 distance
restraints derived from 159 intraresidue, 110 sequential, 184
medium and long range NOEs, 28 hydrogen bond restraints
defining a total of 14 hydrogen bonds, and 23 f and 10 x1
dihedral angle restraints. A total of 47 of 50 structures con-
verged to a consensus fold, with no NOE distance violation
greater than 0.2 Å and no dihedral violations greater than 3°.
Of these, the 20 lowest energy structures were chosen to rep-
resent the structure of CVID. The structures are exceptionally
well defined, with a backbone pairwise root mean squared
difference of 0.35 Å (calculated over all residues). The angular
order parameters (S) for the f and c backbone dihedral angles
had average values of 0.99, indicating a high degree of struc-
ture precision that is reflected in the low average root mean
squared difference to the mean structure of 0.24 Å.
The CVID structures are shown superimposed globally over
the backbone atoms, together with the lowest energy structure
displayed in secondary structure mode in the same orientation
(Fig. 8A). The same structures are shown rotated 90°y, to dis-
play side chains of residues in loops 2 and 4 which are impor-
tant for binding (Fig. 8B). As for other v-conotoxins, the sec-
ondary structure of CVID is dominated by a triple-stranded
b-sheet, in this case incorporating residues 729 and 25227 as
the two peripheral strands and residues 19221 as the central
b-strand. Other secondary structural features include a
TABLE II
Potency (nM) of v-conotoxins to inhibit 125I-GVIA (N-type) or 125I-MVIIC (P/Q-type) binding to rat brain VSCCs, and
contractions of electrically stimulated rat vas deferens
v-
Conotoxin
Displacement of 125I-GVIA,
IC50 (95% CI)
Inhibition of vas deferens,
IC50 (95% CI)
Displacement of 125I-MVIIC,
IC50 (95% CI)
CVIA 0.56 (0.44–0.70) 205 (170–250) 850 (700–1020)
CVIB 7.7 (7.1–8.5) 630 (480–830) 11 (9.0–13)
CVIC 7.6 (7.0–8.3) 410 (290–590) 31 (26–37)
CVID 0.070 (0.058–0.077) 18.4 (16–21) 55,000 (49,000–62,000)
MVIIA 0.055 (0.047–0.066) 18.2 (15–22) 440 (380–520)
GVIA 0.038 (0.030–0.047) 4.9 (4.0–6.0) 1050 (830–1320)
MVIIC 7.0 (5.3–9.8) 0.60 (0.49–0.72)
FIG. 4. Saturation binding of 125I-CVID and 125I-MVIIA to rat
brain membrane. Specific binding (open symbols) was best fitted by
rectangular hyperbola describing a single binding site. The correspond-
ing solid symbols represent nonspecific binding determined in the pres-
ence of an excess of the corresponding non-iodinated peptide.
FIG. 5. v-Conotoxin inhibition of electrically stimulated rat
vas deferens. A, contractile response of guinea pig vas deferens to
increasing concentrations of CVID, followed by washout. The inset
compares single twitch responses recorded before (1), during (2), and
after washout (3) of CVID, as indicated. B, concentration-dependent
inhibition of rat vas deferens twitches by CVIA–D, MVIIA, and GVIA.
Note the steep Hill slopes for CVID and MVIIA, and the incomplete
inhibition caused by CVID, GVIA, and MVIIA.
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b-bridge composed of residues 122 and 14216 and several
b-turns. The b-turns that link the b-sheet and b-bridge regions
comprise residues 326 (type II), 9212 (type I), 10213 (type I),
15218 (type I), and 21224 (type IV). The b-bridge has not
previously been reported explicitly for other v-conotoxins but is
likely to exist in MVIIA, GVIA, and MVIIC and has been
identified in k-conotoxin PVIIA, which adopts the same struc-
ture as the v-conotoxins but targets the Shaker potassium
channel (35). Structural features of CVID that have not been
described for other v-conotoxins are the presence of two hydro-
gen bonds from the NH protons of Lys10 and Leu11 to the C5O
oxygen atoms of Gly22 and Thr23, respectively. It is likely that
these enhance the stability of loop 2 in CVID compared with
other v-conotoxins. Importantly, the backbone of Tyr13 is sta-
bilized in the aL conformation, with the x1 side chain torsion
angle at 260°. NMR data confirming this conformation for
Tyr13 in CVID include the presence of a strong intraresidue
NHi-Hai NOE, together with a weaker Hai21-NHi and a
3JNH-Ha coupling constant of 7 Hz (36). Attempts to define the
conformation of Tyr13 in other v-conotoxins have been ambig-
FIG. 6. CVID and MVIIA inhibition
of ionic current arising from the pe-
ripheral (a1B-b) and central (a1B-d)
splice variants of the rat N-type
VSCC expressed in Xenopus oocytes.
A and B, inhibition by CVID of typical
depolarization-activated Ba21 currents
through a1B-d in the absence (A) or pres-
ence (B) of rat b3. C and D, dose-depend-
ent inhibition of peak Ba21 current am-
plitude through peripheral (triangles) and
central (circles) N-type VSCCs by CVID
(C) and MVIIA (D), in the presence (open
symbols) and absence (closed symbols) of
rat b3.
TABLE III
Potency (nM) of CVID and MVIIA to inhibit Ba21 current through
central (a1B-d) and peripheral (a1B-b) splice variants of the rat N-type
VSCC in the presence or absence of rat b3 (n 5 3–5)
Subunit combination CVID MVIIA
a1B-d 0.0037 6 0.0006 0.45 6 0.21
a1B-d 1 b3 2.0 6 0.7 1.4 6 0.5
a1B-b 0.23 6 0.05 1.2 6 0.6
a1B-b 1 b3 2.8 6 0.02 11 6 6
FIG. 7. Secondary Ha shifts (ppm) for CVIA–D compared with
MVIIA.
FIG. 8. The three-dimensional structure of CVID. A, a view of the
20 lowest energy structures of CVID superimposed over the entire
backbone, with loops 1–4 indicated. Adjacent is one structure shown in
the same orientation highlighting the b-bridge and sheets (red arrows),
the turns (blue arrows), and the location of disulfide bridges (ball-and-
stick). B, structures in A rotated 90°y, showing the positions of side
chains of residues in loops 2 and 4 that may contribute to the activity of
CVID at N-type VSCCs, including a new interaction through Val24.2
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uous, and indeed Tyr13 may adopt an averaged conformation in
other v-conotoxins. The enhanced structural stability of CVID
is further reinforced by a comparison of the Hb shifts of CVID
and MVIIA (Fig. 9C). The Hb protons of Cys20 are degenerate
in MVIIA indicative of disulfide bond isomerization, whereas
the corresponding protons in CVID have disparate shifts indic-
ative of an absence of any disulfide bond isomerization. The Hb
shifts differences of Cys8, Tyr13, and Asp14 are also signifi-
cantly greater in CVID than in MVIIA. This trend is followed
over the temperature range 2802298 and the pH range 326
(data not shown).
DISCUSSION
By using assay-directed fractionation, we have isolated four
new v-conotoxins from C. catus, named v-conotoxins CVIA–D.
These four conotoxins were chemically synthesized and folded
to be indistinguishable from the native peptides. C. catus is the
sixth piscivorous cone snail to evolve mammalian active
v-conotoxins for prey capture. Analogous to other v-conotoxins
identified to date, CVIA–D have three disulfide bonds, fall
within the mass range 250023600 Da (4), and are relatively
hydrophilic. Inspection of the sequences in Table I reveals a
conserved cysteine framework and three conserved residues
Gly5, Tyr13, and Ser19 (CVID numbering) among v-conotoxins.
Homology at loops 1–4 varies from 0 to 60% sequence identity
among these v-conotoxins, with the largest difference occurring
in loop 4 of CVID. Cloning and sequencing of mRNA transcripts
from the venom ducts of two specimens of C. catus confirmed
CVIA and CVID are expressed in this tissue. Our inability to
isolate mRNA transcripts encoding CVIB and CVIC was most
likely associated with the relatively low abundance of these
peptides. Variation in the levels of specific peptides between
individual C. catus could also be involved.2 Isolation of cDNA
templates for CVIB and CVIC may require the analysis of
additional C. catus specimens or the use of additional “PCR
markers” that are more specific for the mature peptide
sequences.
CVIA–D each fully displaced 125I-GVIA and 125I-MVIIC
binding to rat brain membrane. CVID, GVIA, and MVIIA were
similarly potent at rat brain N-type VSCCs. However, CVID
was 100-fold more selective than MVIIA for N-type over P/Q-
type VSCCs, and 125I-CVID bound to 30% fewer sites in rat
brain membrane than 125I-MVIIA. Similar differences in Bmax
were not observed in saturation binding of 125I-CVID and 125I-
MVIIA to human brain membrane, suggesting that pharmaco-
logical differences exist in the N-type VSCCs present in rat and
human brain. Further studies are required to determine the
origin of these differences. CVIA2D were reversible inhibitors
of peripheral N-type VSCCs involved in neurally evoked trans-
mitter release in rat vas deferens. Inhibition of neurotransmit-
ter release was positively correlated with the displacement of
125I-GVIA binding, consistent with N-type VSCCs being the
major source of Ca21 influx contributing to neurotransmitter
release in the rat vas deferens stimulated at low frequencies
(37–40). A correlation between inhibition of Ca21 influx and
ligand displacement at the N-type VSCC was shown for a series
of MVIIA and TVIA analogues (41) but not for a series of GVIA
analogues (33). Potency estimates obtained using the vas def-
erens were lower than estimates obtained from radioligand
displacement studies (Table II), consistent with previous ob-
servations (37, 42). The relatively high levels of Ca21 in the
physiological solution for the vas deferens compared with the
binding assays is likely to contribute to this difference in po-
tency, since Ca21 is a non-competitive inhibitor of v-conotoxin
binding (13). CVID had no effect on contractions of the vas
deferens induced by exogenously applied ATP or norepineph-
rine or on voltage-sensitive sodium channels in rat autonomic
neurons.2
In Xenopus oocytes, CVID and MVIIA inhibited the inward
current through central (a1B-d) and peripheral (a1B-b) splice
variants of the rat N-type VSCC. In the presence of rat b3
subunit, chosen because it assembles with a1B (43) and is
widely distributed in rat brain (44), MVIIA and CVID had
FIG. 9. Comparison of CVID and MVIIA (55) structures. Shown
in the same global orientation are the backbone superimposition of the
20 lowest energy structures of CVID (green) (A), and a set of 34 struc-
tures of MVIIA (gray backbone, Protein Data Bank code 1DW5, see Ref.
55) comprising both x3 families that were calculated with a force con-
stant of 40 kcal/mol applied to the three disulfide bridge dihedral angles
Cbi–Sgi–Sgj–Cbj (B). The disulfide bridge Cys
8–Cys20 (purple), and the
side chains of important binding residues Arg10 (Lys10 in CVID) (blue),
Leu11 (yellow), and Tyr13 (orange) are identified. The position of loop 4
is indicated in A and B. C shows a comparison of differences in Hb shifts
for selected residues of CVID (green) and MVIIA (gray, 30). Note that
CVID has greater separations of Hb shifts, particularly at Cys8, Tyr13,
Asp14, and Cys20.
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similar potencies. However, the potency of MVIIA and CVID
increased at a1B-d and a1B-b expressed in the absence of rat b3.
This increase was most pronounced for CVID at a1B-d (up to
540-fold), intermediate for CVID and MVIIA at a1B-b (;10-
fold), and least pronounced for MVIIA at a1B-d (3-fold). Previous
studies have shown that the b subunit can influence the affin-
ity of local anesthetics (45) and spider toxins (46) for a1A
(P/Q-type) calcium channels expressed in oocytes and mamma-
lian cells. Oocytes express low levels of an endogenous b sub-
unit (b3xo) with high homology to rat b3 that is essential for
expression of functional channels, and overexpression of either
of these b3 subunits causes the same facilitation of VSCC
current activation and inactivation (47). We propose that ex-
pression of excess b3 can differentially modify v-conotoxin
pharmacology at central and peripheral splice variants of the
N-type VSCC, presumably by binding to an intracellular do-
main of a1B to cause an extracellular conformational change
that reduces v-conotoxin binding.
The alternatively spliced a1B-d and a1B-b differ at extracellu-
lar loops IIIS3-S4 (1SFMG and 2SFMG, respectively) and
IVS3-S4 (2ET and 1 ET, respectively), indicating that rela-
tively small changes in the sequence of a1B not only influence
channel kinetics (insertion of ET in a1B-b slows activation ki-
netics (48)), but modify v-conotoxin pharmacology. Since
v-conotoxins bind preferentially to the inactivated state than
the resting state of N-type calcium channels (49), the observed
effect is not through excess b subunit that would act to increase
the proportion of channels in the inactivated state (47). This
auxiliary subunit effect may occur through the action of excess
b subunit at a second site that is present at the C terminus of
a1A, a1B, and a1E (50), but a differential effect of rat and
Xenopus b3 on the pharmacology of v-conotoxins may also be
involved. The potency of Aga IVA and funnel web spider toxin
were reduced ;10-fold when a1A was coexpressed in mamma-
lian cells with b3 or b2, rather than with b1b (46). The extent
to which v-conotoxin pharmacology at central and peripheral
splice variants of a1B is influenced by different combinations of
the five a2/d subunits and the four b subunits requires further
investigation, given the heterogeneity of a1B/auxiliary subunit
combinations in the brain (43). The differential effect of b
subunits on v-conotoxin pharmacology at central and periph-
eral splice variants of a1B may lead to the development of
v-conotoxins with selectivity for specific forms of the N-type
VSCC present in different neural pathways. However, the pre-
cise location of specific combinations of a1B splice variants and
different b subunits have not yet been determined.
The ability of CVID to discriminate among different forms of
the N-type VSCC may also have therapeutic implications. In a
Freund’s complete adjuvant model of inflammatory pain in
rats, chronic intrathecal administration of CVID (AM336; 0.36
nmol/h) produced sustained antinociception with mild behav-
ioral side effects (mean scores 0.5–1 on a scale of 7) over a 7-day
infusion period. In comparison, MVIIA (Ziconotide; 0.1 for first
24 h and 0.13 nmol/h for next 6 days) produced similar initial
levels of antinociception that returned to base line by day 6,
whereas levels of motor side effects (mean scores 3–4) were
greater and maintained throughout the 7-day infusion period
(52).3 These effects of MVIIA and CVID were completely re-
versed on ceasing conotoxin infusion. CVID has recently gained
approval to enter clinical trials for the treatment of severe pain.
1H NMR studies reveal that CVID adopts a unique fold, with
loop 4 curved toward loop 2 to create a globular surface. In
contrast, loop 4 is oriented parallel to loop 2 in MVIIA and
MVIIC and away from loop 2 in GVIA (18, 30, 53, 54). The
presence of two hydrogen bonds between loops 2 and 4 in CVID
favor loop 4 in this orientation, whereas hydrogen bonds be-
tween loops 2 and 4 have not been reported previously for
GVIA, MVIIA or MVIIA. Early structural studies on MVIIA
(30) raised the possibility of loop 2 instability, based on the
observation of broadened lines in this region. This was sup-
ported by a recent study on the dynamics of MVIIA (55), where
it was suggested that the motion of loop 2 was facilitated by
isomerization of the disulfide bridge between Cys8 and Cys20.
In that study, the introduction of a force constant of 40 kcal
mol21 into the empirical force field restrained the x3 angle of
this disulfide bridge to 690° resulting in two closely related
families of structures (55). No such isomerization is evident in
CVID, where a corresponding force constant of only 10 kcal/mol
yielded a conformation of 190° in all structures. In addition,
the x1 angles at Cys20 for MVIIA (1180°) and CVID (260°)
differed significantly, as do the magnitude of Hb2/Hb3 shift
differences of AMX residues (Fig. 9C). The greater Hb shift
differences of Cys8, Cys20, Tyr13, and Asp14 in CVID indicate
that the side chains of these residues undergo less conforma-
tional exchange than MVIIA. The improved stability of this
disulfide bridge in CVID together with the interloop hydrogen
bonds may act to restrain loop 2 motion, providing an entropic
advantage for binding. This overall stability of CVID is also
likely to contribute to its selectivity, since loop 2/4 combina-
tions contain many of the primary determinants for v-cono-
toxin selectivity between N-type and P/Q-type VSCCs (18).
CVID and two closely related families of MVIIA (55) struc-
tures are compared to highlight important differences in the
orientation of loops 4 and 2 (Fig. 9). Although Tyr13 occupies
similar spatial positions, the positions of the side chains of the
important binding residues 10 and 11 appear reversed in the
two peptides. According to Atkinson et al. (55), motion in
MVIIA results in time-averaged NOEs that ultimately produce
flaws in the resulting structure. Such motion does not appear
to be present in CVID, since no line broadening is observed in
loop 2 or elsewhere in the peptide. This, together with the
increased number of distance restraints, particularly in the
loop 2 region, ensures that the structure of CVID is represented
by a single, well defined conformation. Interestingly, CVID
lacks the secondary binding residues present in loop 4 of
MVIIA (Arg21) (34) or GVIA (Lys24 and Tyr22) (33) but utilizes
a new v-conotoxin/VSCC interaction through the relatively
exposed Val24.2 These structural features presumably act in
concert to influence the selectivity of CVID, as well as provid-
ing a well defined template for pharmacophore development
and the design of peptidomimetic inhibitors of N-type VSCCs.
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